Definium Therapeutics, Inc. (DFTX) vs Erasca, Inc. (ERAS)
A side-by-side comparison of Definium Therapeutics, Inc. and Erasca, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
DFTX
Definium Therapeutics, Inc.
$35.08HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT
ERAS
Erasca, Inc.
$14.27HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT
Total return — DFTX vs ERAS
growth of $100 · dividends reinvested · last 5yDFTX -23.8% (-5.3%/yr)ERAS -15.5% (-3.3%/yr)ERAS compounded faster over this window
DFTX ERAS
DFTX vs ERAS: by the numbers
- •ERAS is the larger company ($4.96B vs $4.66B market cap).
Metrics side by side
Valuation
| Metric | DFTX | ERAS |
|---|---|---|
| P/B ratio | 5.07 | 13.69 |
Profitability
| Metric | DFTX | ERAS |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -38.51% | -79.37% |
| ROIC | -23.81% | -38.03% |
Growth (annualized)
| Metric | DFTX | ERAS |
|---|---|---|
| Total return CAGR (5Y) | 1.43% | -8.34% |
Frequently asked
- How have DFTX and ERAS total returns compared?
- Over the past 5 years, DFTX delivered 1.43% and ERAS delivered -8.34% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.